HUMA - Why Humacyte Stock Is Trading 15% Higher Monday | Benzinga
Humacyte, Inc. (NASDAQ:HUMA) is moving higher on Monday after receiving the Food and Drug Administration’s Regenerative Medicine Advanced Therapy (RMAT) designation for its Acellular Tissue Engineered Vessel (ATEV).
What To Know: This is the biotechnology company’s third time receiving the RMAT designation which is designed to expedite the development and review of therapies for serious conditions.
The designation was specifically granted for the ...